Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.
Ahmed I GadNevin F IbrahimNoura Abdulla AlmadaniRasha MahfouzHanaa A NofalDina S El-RafeyHossam Tharwat AliAmr T El-HawaryAyman Magd Eldin Mohammad SadekPublished in: Diseases (Basel, Switzerland) (2024)
Semaglutide improves lipid profile, liver steatosis, and fibrosis parameters and reduces the BMI in T2D and obese patients with NAFLD.